论文部分内容阅读
乳腺癌组织中,雌激素受体的有或无,可以预示该肿瘤对内分泌治疗的反应。据报道。乳腺癌雌激素受体阳性病人约2/3可望从内分泌治疗中得到客观上的缓解;受体含量越高,肿瘤对内分泌治疗反应的机率越大。目前检测肿瘤组织受体的方法有多种,本文采用一种简便、灵敏的DCC法(Dextran-Coated Charcoal Procedure)测定人乳腺癌组织雌二醇受体的含量为临床提供内分泌治疗的依据。并且对实验中某些影响因素进行了实验探讨。
The presence or absence of estrogen receptors in breast cancer tissue may predict the tumor’s response to endocrine therapy. According to reports. Approximately two-thirds of patients with estrogen receptor-positive breast cancer are expected to receive objective remission from endocrine therapy. The higher the receptor level, the greater the chance that the tumor will respond to endocrine therapy. At present there are many ways to detect the receptor of tumor tissue. In this paper, a simple and sensitive Dextran-Coated Charcoal Procedure was used to determine the level of estradiol receptor in human breast cancer tissue for providing clinical basis for endocrine therapy. And some influencing factors in the experiment were discussed experimentally.